Osivax and GC Biopharma announced a new alliance aimed at developing a more advanced influenza vaccine. The vaccine is set to combine OVX836 and GC FLU. Osivax secured those rights for pursuing a combo shot.
Older adults are facing four vaccine decisions this fall, while the federal immunization calendar continues to carry a 2025 date. Flu and pneumonia deaths have fallen for 25 years, but one American age group recorded a rise.